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Abstract
Kidney transplantation is a safe and effective option for HIV-positive (HIVþ) patients. We conducted a retrospective
study on HIVþ kidney transplant recipients who underwent transplantation from March 2008 to September 2016.
Inclusion criteria for transplantation were CD4þ T-cell count 200 per mm3 and undetectable HIV load. The current
study reports the outcome of 19 HIVþ recipients, mostly of Caucasian origin (79%) with a median age of 50 years
(interquartile range [IQR], 42–52), who were followed up for a median period of 2.4 years (IQR, 1.2–4.6) after trans-
plantation. Compared with HIV-negative (HIV) controls, HIVþ recipients had similar one- and three-year graft and
patient survival, but significantly lower five-year patient survival (P¼ 0.03). The differences in graft outcome became less
evident with the analysis of death-censored graft survival rates. Cumulative incidence of allograft rejection at one year
was 32.9%. Rates of infections were not particularly elevated and HIV replication remained well controlled in all but one
patient. A high prevalence of metabolic and endocrine complications (68%) was reported after transplantation. Further
studies are needed to evaluate long-term outcomes of HIVþ recipients who underwent kidney transplantation.
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Introduction
HIV infection continues to be a major public health
challenge worldwide. Despite a slight reduction of inci-
dence, global prevalence of HIV tends to increase
steadily as people on antiretroviral therapy live
longer.1–3 Although the advent of highly active antire-
troviral therapy (HAART) has substantially improved
morbidity and mortality of HIV-positive (HIVþ)
patients,4–6 the prevalence of comorbidities has
increased with increasing prevalence of people living
with HIV. End-stage renal disease (ESRD) is one of
the most serious complications7 and a leading cause
of death8 in patients infected with HIV. Kidney trans-
plantation has been considered the best renal replace-
ment treatment option for HIVþ patients reaching
ESRD as it is safe and effective; moreover, it is associ-
ated with an increase in life expectancy.9 Key factors
for a successful kidney transplantation rely essentially
on the beneficial effect of HAART5,10 and the absence
of detrimental effects of immunosuppressive therapy
on HIV progression. Over the years, several studies
have shown excellent patient and graft survival rates,
similar to uninfected kidney transplant (KT) recipi-
ents.9,11–14 However, the interpretation of these data
1Nephrology Dialysis and Transplant Unit, University of Modena and
Reggio Emilia, AOU Policlinico of Modena, Modena, Italy
2Clinic of Infectious Diseases, University of Modena and Reggio Emilia,
AOU Policlinico of Modena, Modena, Italy
Corresponding author:
Gaetano Alfano, Specialist in Nephrology, AOU Policlinico of Modena,
Via del Pozzo, 71, 41124 Modena, Italy.
Email: gaetano.alfano.md@gmail.com
International Journal of STD & AIDS
0(0) 1–11
! The Author(s) 2018
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0956462418779659
journals.sagepub.com/home/std
is limited principally by short-term follow-up (less than
five years) of the above-mentioned studies, which
should not be considered as representative for long-
term outcomes in this vulnerable population.
Since we are aware that several risk factors may
negatively influence long-term patient and graft surviv-
al of HIVþ KT patients, we conducted an observation-
al study aimed at describing the clinical outcomes of
these patients.
Methods
This retrospective study was conducted at the University
Hospital of Modena, an active renal transplant center
that started a program of kidney transplantation of
HIVþ patients from HIV-negative (HIV) deceased
donors in 2008. The eligibility criteria for kidney trans-
plantation were as follows: (i) CD4þ T-cell count con-
sistently 200 cells/mm3 in patients not on antiretroviral
therapy (monitoring of CD4þ T-cell count every three
months); (ii) undetectable HIV viral load (VL) (<50
HIV-1 RNA copies/mL) and CD4þ T-cell count
200 cells/mm3 for at least six months in patients on
antiretroviral therapy; and (iii) presumed good compli-
ance to follow-up and therapy.
We collected and reviewed all data of HIVþ KT
recipients from March 2008 to September 2017, date
of last follow-up. The study was approved by
Institutional Review Board of the University of
Modena and Reggio Emilia.
Immunosuppressive therapy
All recipients received induction therapy with a
monoclonal anti-interleukin 2 receptor antibody
(Basiliximab) at a dose of 20 mg on postoperative
days (POD) 1 and 4.
Two different immunosuppressive protocols were
used as maintenance therapy. From March 2008 to
March 2015, immunosuppressive strategy was based on
calcineurin inhibitor minimization including low dose of
cyclosporine (Cys), everolimus (EVL) and steroid (meth-
ylprednisolone). In the early post-transplant period, Cys
dose was adjusted to achieve a 2-h postdose Cys level
(C2) of 1000–1200 ng/mL. EVL was introduced on POD
21. During the first six months after kidney transplanta-
tion, C2 and target trough level of EVL were maintained
at 400–500 ng/mL and 8–10 ng/mL, respectively, and
were tapered, respectively, to 250–350 and 6–8 ng/mL
after six months. From April 2015, the maintenance
immunosuppression of new HIVþ KT recipients includ-
ed tacrolimus (TAC), mycophenolic acid (MPA) and
steroid (methylprednisolone). TAC was given when cre-
atinine was <3.0 mg/dL; dose was adjusted to achieve
target trough level of 10–12 ng/mL. During the first
six months after KT, target trough level of TAC was
maintained at 8–10 ng/mL and then was tapered to
6–8 ng/mL.
Methylprednisolone was given as follows: 500 mg
intravenously at POD 0, 250 mg at POD 1, 125 mg
at POD 2 and 80 mg at POD 3. From POD 4, oral
prednisolone (16 mg/day) was tapered progressively
until 4 mg/day at the sixth month.
The dose of MPA (360 mg three times daily) was
adjusted according to gastrointestinal tolerability, risk
of infectious diseases and laboratory parameters.
Infectious disease prophylaxis
Patients received trimethoprim-sulfamethoxazole or
pentamidine isethionate for Pneumocystis jirovecii,
at least for 12 months. According to the institutional
protocol, intravenous (IV) ganciclovir or oral valganci-
clovir were given for cytomegalovirus (CMV) prophy-
laxis to all patients regardless of donor/recipient
serology matching for 12 months. Ganciclovir was
administered for the entire length of hospital stay and
then was replaced by oral valganciclovir. From 2010,
valganciclovir was the first-line therapy of CMV pro-
phylaxis in our Center. In case of a CMV-positive
donor and a CMV-negative recipient, anti-CMV
immunoglobulin (Ig) was also administered. CMV,
Epstein-Barr virus (EBV), and human herpes virus
(HHV) 6, HHV-8, polyomavirus BK and JC virus
were monitored according to the Italian National
Kidney Transplant Program guidelines.15
Diagnosis and treatment of acute rejection
Rejection was suspected by a delayed graft function,
rapid increase in serum creatinine concentration
(more than 15%) and new onset or progressive
worsening of proteinuria (approximately> 1 g/day).
Anti-HLA antibodies testing was performed whenever
rejection was suspected. Biopsy-proven acute T-cell-
mediated rejection (TCMR) was treated with IV pulse
of methylprednisolone (250–500 mg daily for three
days). Biopsy-proven antibody-mediated rejection
(AMR) was treated with a combination of plasmaphe-
resis (7 sessions), rituximab (375 per square meter of
body-surface area weekly for four weeks) and high dose
IV Ig (2 g/kg); in case of mixed acute rejection, IV
methylprednisolone was added at a dose of 250–500
mg daily for three days.
Management of HIV infection
An infectious diseases consultant with expertise in HIV
disease managed prescription and monitoring of anti-
retroviral agents. HAART was given in the immediate
postoperative period. Pre-transplant resistance profile
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was obtained from patient history or analyzing HIV
DNA from lymphocytes if the patients had undetect-
able HIV RNA loads. Antiretroviral regimens were
selected in order to maintain an undetectable VL, pre-
vent interactions with immunosuppressive drugs and
avoid undesirable side effects such as nephrotoxicity
(Table 2). Treatment was chosen on the basis of drug
product availability, HIV pre-transplant genotype
profile, individual drug tolerability, hepatitis B virus
(HBV) and hepatitis C virus (HCV) coinfection and
comorbidities.
Clinical outcomes
Measured outcomes included patient and graft surviv-
al; cumulative incidence of acute rejection episodes;
HIV immuno-virological response (HIV RNA VL,
CD4þ T-cell count, and CD4/CD8 ratio); and preva-
lence of metabolic disorders, neoplasms, and serious
infections. In our Center, undetectable HIV VL was
defined as an HIV RNA level lower than 40 copies/mL.
Patient and graft survival rates at one, three, and
five years in HIVþ patients were compared with two
cohorts (entire population and patients aged 65
years) of HIV patients who underwent single kidney
transplantation from deceased donor at our Center
during the same period (from January 2008 to
September 2016). Assessment of kidney function was
performed by estimated GFR using the CKD-EPI
equation.16 Graft loss was defined as return to dialysis
or death with a functioning graft. Delayed graft func-
tion (DGF) was defined as the need of hemodialysis
during the first post-transplant week. Serious infection
event was defined as infection requiring hospitalization.
Diagnosis of HCV infection was made by detection of
HCV RNA at the end of follow-up.
Statistical analysis
Continuous variables are presented as medians and
interquartile ranges (IQRs); ordinal variables and
data about doses of immunosuppressive agents
(Table 2) are presented as meansSD. Prevalence
was expressed as percentages.
Kaplan–Meier curves were used to calculate patient
and graft survival, whereas Wilcoxon–Mann–Whitney
test and analysis were used to evaluate differences in
age among HIVþ patients and HIV controls. Death-
censored graft survival was calculated from the date of
transplantation to the date of last follow-up if graft was
still functioning, or the date of graft failure. Statistical
analysis was performed using the GraphPad Prism
6VR software.
Results
Patients and donors characteristics
We enrolled 19 HIV+ patients who underwent kidney
transplantation from deceased donors. Recipients and
donors characteristics are presented in Table 1.
The median age of recipients was 50 years (IQR,
42–52 years). The majority of the subjects were male
(n¼ 11, 68%) and of Caucasian origin (n¼ 15, 79%).
KT recipients were followed up for a median of 2.4
years (IQR, 1.2–4.6 years). At the time of the analysis,
Table 1. Baseline characteristics of donors and HIV+
KT recipients.
Donor (n5 19)
Age—yr
Median (IQR) 39 (25–43)
Deceased—no. (%) 19 (100)
High infectious risk—no. (%) 7 (37)
Expanded criteria—no. (%) 1 (5)
CMV seroprevalence—% 82
Recipient (n5 19)
Age—yr
Median (IQR) 50 (42–52)
Male sex—no. (%) 13 (68)
Race—no (%)
White 15 (79)
Black 3 (16)
Other 1 (5)
Cause of chronic kidney disease—no. (%)
Unknown 8 (42)
Presumed HIV-associated nephropathy 2 (10)
Chronic pyelonephritis 2 (10)
Membranous glomerulonephritis 2 (10)
Other causes 5 (28)
Dialysis vintage—yr
Median (IQR) 4.3 (2.8–5.7)
Time on waiting list
Median 0.8 (0.3–1.2)
PRA > 80%—no. (%) 3 (16)
HLA mismatch
Mean 3.5
Time since HIV diagnosis—yr
Median (IQR) 15.7 (12.6–23.1)
CD4 T-cell count—cells/mm3
Median 407 (367–556)
CD4/CD8 ratio
Median (IQR) 0.64 (0.46–0.96)
CMV seroprevalence—%
EBV seroprevalence—% 95
HCV infection (RNA detectable)—no. (%) 100
HBV infection (DNA detectable)— no. (%) 2 (10)
Patient on HAART—no. (%) 19 (100)
EBV, Epstein–Barr virus; HAART, highly active antiretroviral therapy; HBV,
hepatitis B virus; HCV, Hepatitis C Virus; HLA, human leukocyte antigens;
IQR, interquartile range; and PRA, panel reactive antibody.
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five patients had completed at least five years of follow-
up. No patient was lost to follow-up.
Slightly less than half of patients (n¼ 8, 42%) had
ESRD of unknown origin. Kidney transplantation
was performed after a median age of 15.7 years
(IQR, 12.6–23.1 years) from the diagnosis of HIV.
Median dialysis vintage was 4.3 years (IQR, 2.8–5.7
years) and median time on waiting list was 0.8 years
(IQR, 0.3–1.2 years). The median cold ischemia time
was 15.8 h (range, 12.2–20 h).
According to local protocol, in the early postopera-
tive period, 11 KT recipients received an immunosup-
pressive treatment including low-dose Cys, EVL, and
steroid. From 2015, eight patients received TAC, MPA,
and steroid. Table 2 summarizes the dose adjustments
of all the immunosuppressive drugs within five years
following transplantation.
The median age of HIV KT recipients was 52
years (IQR, 43–60 years); older recipients (age 65
years) had a median age of 68 years (IQR, 66–70
years). Whereas there were no significant differences
in ages between HIV-infected and the entire
uninfected population (P¼ 0.065), age difference
was significant between older HIV and HIVþ
patients (P  0.0001).
Antiretroviral therapy
Preferred drugs included raltegravir and dolutegravir
for the INSTI class, maraviroc for CCR5 receptor
antagonist, lamivudine for NRTI, and rilpivirine
for NNRTI.
These antiviral drugs were largely used in our Center
as they offered the advantage of having no drug inter-
actions and minimal toxicity. Indeed, 94.7% of patients
were on raltegravir or dolutegravir, 66.6% on lamivu-
dine, and 42.1% on maraviroc or rilpivirine, at the end
of follow-up (Table 3).
On the other hand, some drugs were avoided when
possible: these included boosted regimens and some
NNRTIs (risk of pharmacological interactions), teno-
fovir disoproxil fumarate (risk of renal toxicity), and
abacavir (apparent risk of cardiovascular disease).
Patient and graft survival. Patient survival among all
HIVþ recipients at one, three, and five years was
94.4%, 94.4%, and 70.8%, respectively. One-, three-,
and five-year graft survival rates were 84%, 72%, and
55.6%, respectively. Graft survival censored for patient
death at one, three, and five years was 94.7%, 81.4%,
and 81.7%, respectively (Table 4).
Delayed graft function occurred in 17% (n¼ 3) of
KT recipients. Three patients died with a functioning
graft from cardiovascular causes. Four patients had
graft failure due to AMR (n¼ 2) and allograft nephrec-
tomy (n¼ 2). Only two patients with persistent and
untreated HCV replication had a poor outcome:
one resumed hemodialysis one year after transplanta-
tion owing to complications of severe infectious disease
(suppurative bacterial pyelonephritis caused by
Table 2. Immunosuppressive agents used during follow-up in HIVþ KT recipients.
Month 1 Month 3 Month 6 Month 12 Month 36 Month 60
Patient, n 18 17 17 17 8 5
Cys (C0/C2)1EVL
n (%) 8 (44%) 7 (41%) 7 (41%) 7 (41%) 4 (50%) 2 (40%)
Mean trough level (ng/mL) 116/503 þ7.5 124/551þ 6.9 77/420þ 7.6 71/377þ 6.3 46/263þ 4.7 62/205þ 5.7
TAC
n (%) 9 (50%) 9 (53%) 9 (53%) 6 (35%) – –
Mean trough level (ng/mL) 8.9 7.6 6.3 6.1
SIR
n (%) – – – 3 (18%) 1 (12%) 1 (20%)
Mean trough level (ng/mL) 7.75 6.1 6.1
Cys (C0/C2)
n (%) 1 (6%) 1 (6%) 1 (6%) 1 (6%) 3 (38%) 2 (40%)
Mean trough level (ng/mL) 215/1286 80/542 45/549 121/597 144/557 148/395
MPA
n (%) – 1 (6%) 2 (12%) 3 (18%) – –
Mean dose (mg/day) 1080 720 600
Steroida
n (%) 18 (100%) 15 (88%) 14 (82%) 12 (71%) 4 (50%) 1 (20%)
Mean dose (mg/day) 13.1 7.9 5.4 6.3 2.75 2
Cys: cyclosporine; C0/C2: cyclosporine trough (C0) and 2-h postdose (C2); TAC: tacrolimus; SIR: sirolimus; EVL: everolimus; MPA: mycophenolic acid.
aMethylprednisolone.
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atypical mycobacteria), and one died of a sudden
acute myocardial infarction four years from
transplantation.
Patient, graft, and death-censored graft survival
among all HIV recipients and HIV recipients aged
65 years at one, three, and five years are illustrated in
Table 4 and Figure 1.
Compared with all HIV recipients, HIVþ had sim-
ilar one-year (94.4% vs. 98.9%, P¼ 0.12) and three-
year (94.4% vs. 95.6%, P¼ 0.6) patient survival and
Figure 1. Kaplan–Meier survival curves. Kaplan–Meier estimates of patient (a), graft (b), and death-censored graft survival (c) in
HIVþ and HIV patients who underwent kidney transplantation at our Center during the same time frame. Uninfected kidney
transplant recipients were stratified by age in two groups: older recipients (aged 65 years) and all recipients. HIVþ kidney transplant
recipients had a significantly inferior five-year patient survival rates compared to HIV kidney-transplant recipients (P¼ 0.03) and a
similar rate (P¼ 0.79) compared to older recipients. Five-year graft survival rates of HIVþ recipients were between those reported
for older kidney transplant recipients and for all kidney transplant recipients; there were no significant differences between HIVþ and
all HIV recipients (P¼ 0.14) and HIVþ and older HIV recipients (P¼ 0.44). Death-censored graft survival rates at five years between
HIVþ and all HIV recipients (P¼ 0.72) and HIVþ and older HIV recipients (P¼ 0.54) were not statistically significant.
Table 4. Survival rates by HIV status and additional patient characteristics.
Patient survival (%) Graft survival (%) Death-censored graft survival (%)
Recipient n 1 year 3 years 5 years 1 year 3 years 5 years 1 year 3 years 5 years
HIVþ 19 94.4 94.4 70.8a 89.5 77.1 57.8 94.7 81.4 81.7
HIVb 200 98.9 95.6 92.9c 91.4 82.1 78.3 92.4 85.9 84.3
HIV aged 65 yearsb 33 96.6 88.5 69.5 84.8 66.1 48.7 87.7 74.7 70.0
aStatistically significant difference between HIVþ recipients and all HIV recipients.
bSingle kidney transplantation from deceased donor from January 2008 to September 2016.
cStatistically significant difference between HIV recipients and HIV recipients aged 65 years.
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similar one-year (89.5% vs. 91.4%, P¼ 0.76) and three-
year (77.1% vs. 82.1%, P¼ 0.53) graft survival.
Kaplan–Meier analysis showed that HIVþ patients
compared to all HIV had a significantly inferior
patient survival rate (70.8% vs. 92.9%, P¼ 0.03) and
a non-statistically significant lower graft survival
(57.8% vs. 78.3%, P¼ 0.14) at five years (Table 4 and
Figure 1(a) and (b)).
In contrast, HIVþ recipients, compared to HIV
recipients aged 65 years, had a similar survival rate
(70.8% vs. 69.5%, P¼ 0.794) and non-statistically sig-
nificant higher graft survival rate at five years (57.8%
vs. 48.7%, P¼ 0.44) (Table 4 and Figure 1(a) and (b)).
When death-censored graft survival rates at five years
were evaluated, HIVþ recipients had a similar survival
rate compared to all HIV recipients (81.7% vs.
84.3%, P¼ 0.72), and non-statistically significant
higher survival rates compared to HIV KT patients
older than 65 years (81.7% vs. 70%, P¼ 0.54) (Table 4
and Figure 1(c)).
Allograft rejection. Nine patients (47.4%) had 14 allograft
rejections during the follow-up (Table 5). There were
eight TCMR episodes (57%), four AMR episodes
(29%), one mixed rejection episode (7%), and one
chronic AMR (7%). Half of the episodes of rejection
occurred during the first six months after transplanta-
tion and were mostly TCMR. After one year from
transplantation, AMR was the most common type of
rejection. All cases of acute T-cell rejection were
responsive to high-dose corticosteroids. Acute AMR
occurred in four KT recipients (two women and two
men) after a median age of 1.1 years from transplanta-
tion. Three patients resumed hemodialysis whereas one
patient had severe renal impairment (stage 4 vs. stage 1
of chronic kidney disease) at the end of the follow-up.
The cumulative incidence of rejection at one, three, and
five years was 32.9%, 40.3%, and 48.8%, respectively.
Patients treated with Cys/EVL had a higher one-year
cumulative acute rejection rate than patients treated
with TAC (50% vs. 33.3%) within the first year,
but this difference was not statistically significant
(P¼ 0.64).
Progression of HIV disease. All patients were on HAART
before they underwent kidney transplantation; they
had an undetectable VL, a median CD4þ T-cell
count of 407 cells/mm3 (IQR, 367–556), and CD4/
CD8 ratio of 0.64 (IQR, 0.46–0.96) at time of kidney
transplantation.
The change in the CD4þ T-cell count from baseline
at one, three, and five years after transplantation were
478 (IQR, 414–630), 449 (IQR, 353–714), and 659
(365–791) cells/mm3, respectively. In 18 patients,
plasma HIV-RNA was undetectable at any time after
transplantation. Only one patient had a detectable vire-
mia six years after transplantation that was unrespon-
sive to change in several ART regimens; conversion to
sirolimus (SIR) (target TTL of 5–7 ng/ml) from Cys
and EVL was required to control the rate of viral
replication.
Complication after kidney transplantation. Among 19
kidney transplant recipients, 10 patients (72%) experi-
enced 25 episodes of infections during the follow-up;
hospital admission was required only in 11 cases.
Infections were caused by bacteria (46%) and fungi
(36%); cultures were negative for the remaining 18%.
The site of infection was lung (55%), genitourinary
(36%), and central nervous system (9%). About 70%
of the infections occurred within the first two years
after transplantation.
Three cases of Pneumocystis jirovecii pneumonia
were diagnosed in two subjects with CD4þ T-cell
count higher than 200 cells/mm3. HHV8 viremia was
identified in three patients but only one developed a
Kaposi sarcoma. CMV replication was detected after
specific prophylactic therapy in 2 out of in 15 patients
tested (13%), and only one required specific antiviral
treatment. CMV infection was susceptible to ganciclo-
vir and was treated successfully with valganciclovir.
Detection of EBV replication was found in 15 of 17
patients tested; five patients had a persistent viremia
Table 5. Renal outcome of HIVþ kidney transplant recipi-
ents (n¼ 19).
Median eGFRa (IQR), mL/min/1.13m2
Month 3 70 (48–82)
Month 6 66 (42–78)
Month 12 41 (33–708)
Month 36 53 (36–74)
Month 60 56 (54–58)
Type of rejection (n¼14)
T-cell-mediated 57% (n¼8)
Antibody-mediated 29% (n¼4)
Mixed 7% (n¼1)
Chronic antibody-mediated 7% (n¼1)
Episodes of rejection
6 months
T-cell-mediated 6
Antibody-mediated 1
6–12 months
T-cell-mediated 1
Mixed 1
>12 months
T-cell-mediated 1
Antibody-mediated 3
Chronic antibody-mediated 1
Mixed denotes mixed cellular and antibody-mediated rejection.
aeGFR, estimated glomerular filtration rate using the CKD-EPI
formula.
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from the early post-transplant period to the end of
follow-up. The median EBV-VL was 362 copies/ml
(IQR, 75–2427). Despite the high prevalence of EBV
replication, no patient developed EBV-related post-
transplant lymphoproliferative disease. Of the 17
patients who were tested for polyomavirus BK and
JC virus, peripheral blood viremia was detected in
47% and 18% of patients, respectively. There was
one case of biopsy-proven BK nephropathy.
De novo endocrine and metabolic complications
developed in 14 subjects (68%) after kidney transplan-
tation, including diabetes (43%), hypercholesterolemia
(36%), sarcopenia (29%), cardiovascular events (21%),
hypothyroidism (14%), osteopenia (14%), and osteo-
porosis (7%).
Other complications were two cases of avascular
necrosis of the femoral head, and one case each of
deep venous thrombosis, acute pancreatitis, and demy-
elinating polyneuropathy.
Two patients (11%) underwent graft nephrectomy:
one due to interstitial hemorrhage secondary to acute
AMR rejection and one for suppurative bacterial
pyelonephritis.
Neoplasm. One case of neoplasm was reported. The
tumor was a cutaneous Kaposi sarcoma involving the
skin, diagnosed after 0.9 years from kidney transplan-
tation. Complete tumor resolution was achieved after
two months from diagnosis with withdrawal of immu-
nosuppressive therapy due to graft failure.
Discussion
After the first recognition in 2003 that kidney trans-
plantation was a safe and effective solution for HIV-
infected patients reaching ESRD,17 HIV infection was
no longer considered an absolute contraindication to
transplantation. Although prospective12,17,18 and retro-
spective studies13,19 have reported promising results,
HIV-associated comorbidities, high prevalence of
acute allograft rejections, and the lack of consensus
guidelines for the management of immunosuppression
have the potential to negatively affect long-term out-
comes of transplantation in HIVþ patients. With the
present study, we report clinical outcomes of 19 HIVþ
subjects who underwent kidney transplantation from
deceased donors. The study, conducted among patients
with a median age of 50 years and mainly of Caucasian
origin, showed excellent graft and patient survival rates
at one year and three years. These data were highly
comparable with those observed in HIVKT recipients
transplanted at our center during the same time frame.
When we extended analysis out to five years, we found
a significantly lower patient survival rate (70.8% vs.
92.9%, P¼ 0.03) and a non-significant trend toward
reduced rates of graft survival (57.8% vs. 78.3%,
P¼ 0.14) compared with the general pool of
HIV recipients.
Interestingly, the difference between graft survival
rates became less evident when data were censored
for death (81.7% vs. 84.3%, P¼ 0.72), indicating a sub-
stantial impact of mortality on long-term graft out-
come in HIVþ patients.
Overall, HIVþ recipients had survival rates gener-
ally between rates found in all HIV-uninfected recip-
ients and recipients older than 65 years, a tendency
already noted by Stock et al.12 in a larger population
of HIVþ KT recipients. These findings suggested that
HIVþ recipients had an higher risk of death than
uninfected controls of the same age. We hypothesize
that T-cell senescence, advanced atherosclerosis, and
non-AIDS-related disorders may be the leading
causes of exitus in this group of subjects. First,
patients with HIV may have T-cell dysfunction20 sim-
ilar to older patients that contributes to the increased
incidence of morbidity and mortality from infectious
disease, and possibly autoimmunity and cancer.21
Second, both age and HIV infection22 lead to
increased likelihood of developing atherosclerosis
and small vessel disease which generally predisposes
to coronary and cerebrovascular events. Finally it is
well-known that, in the HAART era, non-AIDS-
related disorders, such as cardiovascular disease,
cancer, and liver disease, are the major causes of mor-
bidity and mortality among these patients.23,24 We
believe that despite careful patient selection, the first
patients who were enrolled for kidney transplantation
could have had a potentially poorer outcome com-
pared to both actual HIVþ patients and non-
infected counterparts. Probable causes may have
been inadequate management of HIV disease during
the late 1980s and 1990s, when control of VL was
particularly challenging and delay in diagnosis, link-
age to care, and treatment were particularly common.
A major concern in our study was the high frequen-
cy of episodes of allograft rejections that have been
associated with a 2.8-fold greater risk of graft loss in
the setting of HIV infection.12 In line with the current
literature that estimates the one-year cumulative inci-
dence of acute rejection up to 52%,12,25 we detected a
rate of 32.9% in our HIVþ population. The episodes of
rejection, developed mainly during the first six months
after transplantation, were mostly T-cell mediated and
responsive to glucocorticoid. Beyond one year from
transplantation, AMR became prevalent. The treat-
ments of rejection were well tolerated, without the
development of opportunistic infections or any signifi-
cant drop in CD4þ T-cell count.
The causes of the increased risk of rejection in HIVþ
KT patients are still unclear. Stock et al.12 proposed
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that several mechanisms related to the chronic HIV
infection may be responsible for an excessive allogeneic
response against graft antigens; in fact, HIV is able to
incorporate HLA molecules of the host into its genome
that may induce allosensitisation and is able to increase
the responsiveness of T-lymphocyte and stimulation of
memory alloreactive T lymphocyte due to cross-
reactivity. In light of our results, we presume that our
past tendency to minimize immunosuppression, in
order reduce the risk of infection, could have contrib-
uted to the high rates of rejection in this cohort of
patients. According to this hypothesis, both Gruber
et al.26 and Touzot et al.13 reported low rejection
rates at one year (13 and 15%, respectively) in patients
treated with anti-IL-2 for induction and a standard
triple calcineurin inhibitor-based immunosuppression
for maintenance, without documenting a high inci-
dence of opportunistic infections. Given that, there is
a growing awareness that HIVþ KT recipients should
receive the same amount of immunosuppressive thera-
py as HIV patients, our past strategy aiming at main-
taining HIVþ KT recipients on low-grade
immunosuppression (EVE with low-dose Cys and ste-
roid) has been definitely abandoned. On the basis of
these observations, we enhanced immunosuppressive
therapy using a standard protocol based on TAC,
MPA, and steroid. TAC was preferred to Cys because
was superior in preventing rejection as demonstrated
also in HIVþ KT recipients.27
Infections have been reported as common complica-
tions of kidney transplantation. In our group of HIVþ
KT recipients, infections were mainly bacterial and
resolved with appropriate antibiotic therapy.
Pneumocystis jirovecii pneumonia occurred three
times in two patients after more than two years from
transplantation; a CD4þ T-cell count 200 cells/mm3
at the time of the event suggests that these infections
were a complication of the immunosuppressive therapy
rather than AIDS-defining illnesses.28
Surprisingly, the rate of CMV replication was excep-
tionally low in our HIVþ patients; only one subject
required specific therapy. The low rates of CMV vire-
mia were probably due to the high rate of CMV sero-
prevalence among recipients (95%), and the efficacy of
extended valganciclovir prophylaxis after kidney trans-
plantation.29,30 We underline that prolonged duration
of CMV prophylaxis (12 months) was dictated by the
institutional protocol and not by the current recom-
mendations in HIVþ KT recipients. Given that CMV
infection does not seem particularly prevalent in this
population, the standard approach is to perform CMV
prophylaxis similar to HIV KT recipients.
Overall, HIV-infected KT recipients did not display
an increased susceptibility to opportunistic and non-
opportunistic infections. The ability to mount an
efficacious immune response, as evidenced by the
high rate of allograft rejections, apparently indicates
a preserved immune response towards pathogens in
these subjects. In accordance with the findings of the
present report, there was no evidence of an accelerated
progression of HIV infection after KT. Only one
patient experienced recurrent viraemia poorly con-
trolled by HAART; in this case, the switch of immu-
nosuppression from Cys to SIR reduced the rate of
detectable viremia leading to a more stable control of
HIV infection.
After transplantation, more than half of our patients
developed de novo metabolic complications including
diabetes, cardiovascular disease, sarcopenia, and
hypercholesterolemia. Main causes of these complica-
tions relied on a combination of pre-existing risk fac-
tors such as HIV infection,31 antiretroviral therapy,32–
34 and well-known side effects of immunosuppressive
therapy (e.g. steroids, calcineurin inhibitor) post-
transplantation.
Our study has several limitations. The main short-
comings include the small number of patients, the short
interim follow-up and the retrospective design of the
study. Sample size is too small to assess the association
of recipient mortality and graft loss with different
demographic and clinical variables. We cannot evalu-
ate if HIVþ KT recipients were exposed to more
adverse events compared to their uninfected counter-
part because the rates of metabolic complications, allo-
graft rejections, and infections between the two groups
have been not compared.
Moreover, it is worth noting that the limited number
of subjects (n¼ 5) at the end of the five-year follow-up
is inadequate to properly assess long-term graft out-
comes; therefore, our results cannot be generalized to
all HIVþ KT recipients. However, this study provides a
thorough analysis of long-term follow-up from one of
the few cohorts of HIV-infected recipients of kidney
transplantation worldwide.
In conclusion, our study presents clinical outcomes
of a small series of HIVþ KT recipients mostly of
Caucasian origin. Analysis of patient and graft out-
comes confirms an excellent survival at one year and
three years post-transplantation. On the other hand,
there was a significant tendency toward inferior long-
term patient survival, similar to HIV recipients aged
65 years, which influenced graft outcome. We
reported a high prevalence of allograft rejection epi-
sodes, probably caused by the reduced intensity of
immunosuppression provided to HIVþ patients in
order to reduce the risk of HIV-related opportunistic
infections, which do not appear to be particularly
increased in our cohort. Larger multicenter studies
are needed in order to evaluate the best immunosup-
pressive treatment for HIVþ KT patients, for the sake
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of improving long-term outcomes and reducing the
prevalence of metabolic complications.
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